Page last updated: 2024-12-11

l-454,560

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L-454,560: Phosphodiesterase Inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9853498
CHEMBL ID372575
SCHEMBL ID4027148
MeSH IDM0494134

Synonyms (21)

Synonym
l-454560
CHEMBL372575 ,
SCHEMBL4027148
bdbm50174022
8-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline
(e)-8-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline
g6gso9sdnj ,
unii-g6gso9sdnj
quinoline, 6-(1-methyl-1-(methylsulfonyl)ethyl)-8-(3-((1e)-2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)ethenyl)phenyl)-
mk-0359
346629-30-9
6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[(e)-2-(4-methanesulfonyl-phenyl)-2-(3-methyl-[1,2,4]oxadiazol-5-yl)-vinyl]-phenyl}-quinoline
l 454560
l-454,560
3-methyl-5-[(e)-1-(4-methylsulfonylphenyl)-2-[3-[6-(2-methylsulfonylpropan-2-yl)quinolin-8-yl]phenyl]ethenyl]-1,2,4-oxadiazole
mk0359
gtpl9852
(e)-3-methyl-5-(1-(4-(methylsulfonyl)phenyl)-2-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)vinyl)-1,2,4-oxadiazole
6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3-[(e)-2-(4-methanesulfonyl-phenyl)-2-(3-methyl-[1,2,4]oxadiazol-5-yl)-vinyl]-phenyl)-quinoline
Q27278833
AKOS040753082
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)0.52000.00002.800510.0000AID314159; AID363352; AID388714; AID447672; AID605111
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)IC50 (µMol)0.00110.00001.068010.0000AID257446; AID257447; AID388710; AID447673; AID502800; AID605106
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)IC50 (µMol)0.00080.00001.104010.0000AID257446; AID257447; AID447673; AID502801; AID605106; AID605107
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)IC50 (µMol)0.00370.00001.465110.0000AID257446; AID257447; AID257448; AID447673; AID502802; AID605106
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.00100.00001.146310.0000AID257446; AID257447; AID257449; AID447673; AID502803; AID605106; AID605108
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)49.90000.00091.901410.0000AID388712
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (65)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
signal transductioncAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
sensory perception of smellcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of protein kinase A signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
neutrophil homeostasiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
neutrophil chemotaxiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
leukocyte migrationcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to lipopolysaccharidecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
nucleoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
ruffle membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
synaptic vesiclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
postsynaptic densitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
Z disccAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
dendritic spinecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
excitatory synapsecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
extracellular spacecAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
ciliumcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (79)

Assay IDTitleYearJournalArticle
AID605277Ratio of drug level in brain of lister rat to IC50 for PDE4 activity2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID605282Cognitive enhancing effect in Lister rat assessed as change in escape latency pretreated 30 mins before sample phase by water maze delayed matching to position test2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID502802Inhibition of human PDE4C2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
AID314159Inhibition of CYP2C92008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
AID314160Inhibition of PDE4 expressed in SF9 cells2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
AID388724Inhibition of late-phase antigen-induced bronchoconstriction in ascaris-sensitive sheep at 0.5 mg/kg, iv daily for 4 days and antigen challenged after 2 hrs post dose on 4th day2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID257464Cmax in rat at 20 mg/kg, po2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID257459Emetic threshold as plasma concentration in squirrel monkeys after 10 mg/kg oral dose2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID388720Bioavailability in orally and iv dosed dog2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID257447Inhibitory activity against PDE4B2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID388718Cmax in po dosed squirrel monkey assessed after first episode of emesis2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID314168Inhibition of ovalbumin-induced bronchoconstriction in guinea pig at 30 ug/kg, ip2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
AID257454Inhibition of early-phase antigen induced bronchoconstriction in Ascaris sensitive sheep at 0.5 mg/kg/day, iv2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID388717Half life in orally and iv dosed Squirrel monkey2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID447673Inhibition of human PDE42009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
AID605284Drug level in brain of Lister rat during conditional taste aversion test2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID605280Ratio IC50 for PDE4 activity in human whole blood to IC50 for PDE42010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID605108Inhibition of PDE4D2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID314158Inhibition of LPS-stimulated TNFalpha release in squirrel monkey whole blood2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
AID502803Inhibition of human PDE4D2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
AID447674Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced TNFalpha production treated 15 mins before LPS challenge by ELISA2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
AID363105Inhibition of TNFalpha release in human whole blood2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID502804Ratio of IC50 for human PDE4B to IC50 for human PDE4D2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
AID605106Inhibition of PDE4A2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID388713Inhibition of LPS-induced TNFalpha production in Squirrel monkey whole blood2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID447849Therapeutic window, ratio of Cmax in squirrel monkey at 10 mg/kg to IC50 for inhibition of LPS-induced TNFalpha production in squirrel monkey whole blood2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
AID605275Drug level in brain of Lister rat during novel object recognition test2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID314165Cmax in squirrel monkey at 10 mg/kg2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
AID257455Inhibition of late-phase antigen induced bronchoconstriction in Ascaris sensitive sheep at 0.5 mg/kg/day, iv2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID388714Inhibition of CYP2C92008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID388712Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID388723Inhibition of ovalbumin-induced bronchoconstriction in conscious guinea pig at 0.03 mg/kg, ip administered 30 mins before ovalbumin challenge2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID388715Half life in orally and iv dosed rat2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID257446Inhibitory activity against PDE4A2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID447845Cmax in squirrel monkey at 10 mg/kg2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
AID605216Induction of adverse effect in Lister rat assessed as induction of malaise by conditional taste aversion test2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID605109Inhibition of PDE4 activity in human whole blood assessed as inhibition of LPS-induced TNF-alpha release2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID388719Bioavailability in orally and iv dosed rat2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID632293Inhibition of His-tagged catalytic domain Trypanosoma brucei brucei PDEB1 expressed in baculovirus infected insect Sf21 cells at 10 uM2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
AID257467Inhibition of ovalbumin-induced bronchoconstriction in guinea pig at 0.03 mg/kg, ip2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID605274Drug level in plasma of Lister rat during novel object recognition test2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID447844Antiinflammatory activity in squirrel monkey whole blood assessed as inhibition of LPS-induced TNFalpha production treated 15 mins before LPS challenge by ELISA2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
AID632292Antitrypanosomal activity against blood stream Trypanosoma brucei brucei 427 after 48 hrs by Alamar blue assay2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
AID314167Therapeutic index, ratio of plasma concentration causing emesis to IC50 for inhibition of LPS-stimulated TNFalpha release in squirrel monkey whole blood2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
AID257465Oral bioavailability in rat at 20 mg/kg, po2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID257466Tmax in rat at 20 mg/kg, po2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID605276Ratio of drug level in brain to plasma of Lister rat Drug level in plasma of Lister rat during novel object recognition test relative to untreated control2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID257462Inhibition of LPS-induced TNFalpha production in squirrel monkey whole blood2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID447676Clearance in iv dosed rat2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
AID447672Inhibition of human CYP2C92009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
AID388711Inhibition of LPS-induced TNFalpha production in human whole blood2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID388710Intrinsic inhibition of GST-fused human PDE4A expressed in SF9 cells2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID314161Inhibition of LPS-stimulated TNFalpha release in human whole blood2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
AID447671Toxicity in iv dosed squirrel monkey assessed as occurrence of emesis at plasma concentration of 3.8 uM2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
AID502801Inhibition of human PDE4B2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
AID632291Inhibition of His-tagged catalytic domain Trypanosoma brucei brucei PDEB2 expressed in baculovirus infected insect Sf21 cells2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
AID388716Half life in orally and iv dosed dog2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID257449Inhibitory activity against PDE4D2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID605215Cognitive enhancing effect in Lister rat assessed as recognition of novel object at 0.1 mg/kg, po pretreated 90 mins before sample phase by novel object recognition test2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID605278Ratio of drug level in plasma of lister rat during conditional taste aversion test to IC50 for PDE4 activity in rat whole blood2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID363352Inhibition of CYP2C92008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID257463Ratio of emesis threshold plasma concentration over inhibition of LPS-induced TNFalpha production in squirrel monkey whole blood2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID363081Inhibition of PDE42008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID447843Bronchodilator effect in guinea pig assessed as inhibition of ovalbumin-induced bronchoconstriction at 30 ug/kg, ip2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
AID447675Bioavailability in iv dosed rat2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
AID605283Drug level in plasma of Lister rat during conditional taste aversion test2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID605111Competitive inhibition of CYP2C92010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID632290Inhibition of His-tagged catalytic domain Trypanosoma brucei brucei PDEB1 expressed in baculovirus infected insect Sf21 cells2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
AID605107Inhibition of PDE4B2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID257450Inhibition of LPS-induced TNFalpha production in human whole blood2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID257448Inhibitory activity against PDE4C2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
AID388722Ratio of emesis Cmax in Squirrel monkey at 10 mg/kg, po to IC50 for LPS-induced TNFalpha production in Squirrel monkey whole blood2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID502800Inhibition of human PDE4A2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
AID388721Bioavailability in orally and iv dosed Squirrel monkey2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
AID605110Inhibition of PDE4 activity in rat whole blood assessed as inhibition of LPS-induced TNF-alpha release2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
AID1345239Human phosphodiesterase 4D (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2007Biochemical pharmacology, Jun-15, Volume: 73, Issue:12
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
AID1345234Human phosphodiesterase 4B (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2007Biochemical pharmacology, Jun-15, Volume: 73, Issue:12
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
AID1345281Human phosphodiesterase 4C (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2007Biochemical pharmacology, Jun-15, Volume: 73, Issue:12
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
AID1345251Human phosphodiesterase 4A (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2007Biochemical pharmacology, Jun-15, Volume: 73, Issue:12
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (70.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.85 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]